In
this article, Dr John McLaren-Howard very nicely explains the likely reason for this apparent
contradiction in results from the
Lawson et al study (which found
higher than normal ATP levels the cells of ME/CFS patients), and the
Myhill, Booth and McLaren-Howard study (which found
lower than normal ATP levels the cells of ME/CFS patients).
The likely reason for this contradiction is this: the Lawson study used cultured cells (cells taken from ME/CFS patients and then grown in vitro), and McLaren-Howard says using cultured cells would likely fail to account for the effects of any mitochondrial blocking agent that was present in the blood and in the original cells taken from ME/CFS patients.
This is because as you grow new generations of cells in vitro, the blocking agent that was present in the original cells taken from the ME/CFS patient will get diluted down in the new cells, so that the agent will no longer block the mitochondria. Thus the previously blocked mitochondria in the ME/CFS patients' cultured cells are then able to start functioning normally again, and thereby increase their ATP production.
By contrast, the in the Myhill, Booth and McLaren-Howard study, they used cells taken directly from the ME/CFS patients' blood, so they tested the actual cells freshly extracted from the ME/CFS patient.
Dr John McLaren-Howard explains it thusly:
This also links up to the latest metabolic
findings from Fluge and Mella, where they found that healthy muscle cells (myoblasts), when exposed in vitro to the blood serum of ME/CFS patients, developed energy metabolism alterations, including excessive lactate secretion. This finding suggests that there is a mitochondrial blocking agent in the blood serum of ME/CFS patients.
Thus if you grow new cells in vitro, outside of the blood of ME/CFS patients, as they did in the Lawson study, those cells will be healthy and function normally, as they will not be exposed to the blocking agent in the blood. It's the blocking agent in the blood that is the likely cause of the energy metabolism dysfunction in the cells of ME/CFS patients.